European Commission grants conditional approval to CAR-T cell therapy Carvytki (cilta-cel)
The European Commission has granted conditional approval to CAR-T cell therapy Carvytki (cilta-cel) for the treatment of relapsed and refractory myeloma. It has been specifically approved for myeloma patients who have received at least three prior treatments, including a proteasome inhibitor (such as bortezomib and carfilzomib), an immunomodulatory agent (such as lenalidomide or pomalidomide) and an anti-CD38 antibody (such as daratumumab or ixatuximab), and have demonstrated disease progression on last treatment. You can find the full…